- Feeling Appreciated by Partner is Critical for Caregiver’s Mental Health
- Chatbot “Brains” May Slow with Age
- More of America’s Pets Are Overdosing on Stray Coke, Meth
- The Most Therapeutic Kind of Me-Time
- Coffee Can Boost the Brains of People with Certain Heart Conditions
- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
First Device Approved to Prevent Migraines
The first device designed to prevent migraine headaches among adults has been approved by the U.S. Food and Drug Administration.
Cefaly is a battery-powered, headband-like device that’s worn across the forehead. It provides mild electrical stimulation to the trigeminal nerve, which has been associated with migraines, the agency said in a news release. The user may feel a tingling or massaging sensation where the applied electrode touches the skin.
This is the first transcutaneous electrical nerve stimulation (TENS) device approved to prevent pain, the FDA said.
Migraines are characterized by intense throbbing on one side of the head, sometimes accompanied by nausea and sensitivity to light and sound. Untreated, the pain lasts four hours to 72 hours. Migraines are three times more common in women than men, the FDA said.
The device is meant to be used only once daily for 20 minutes. It was evaluated in a Belgian study of 67 people who were prone to getting more than two migraines per month. The device, while shown to be effective among some users, did not completely prevent migraines or reduce their intensity, the FDA said.
The most common adverse reactions were not wanting to continue to use the device because of the electrical stimulation feelings, sleepiness and headache, the agency said. No serious side effects were reported.
The device is produced by the Belgian firm STX-Med.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.